白蛋白结合 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-05. Anything still debated is marked as such rather than presented as settled.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
Upon rewarming, the kidney was transplanted successfully into a rabbit, with complete functionality and viability, able to sustain the rabbit indefinitely as the sole functioning kidney. In 2000, FM-2030 became the first person to be successfully vitrified posthumously.
In the late 20th century, ayahuasca use expanded beyond South America to Europe, North America, and elsewhere, leading to legal cases, non-religious adaptations, and the development of ayahuasca analogues (i.e., variants) using local or synthetic ingredients. While DMT is internationally classified as a controlled substance, the plants containing it—including those used to make ayahuasca—are not regulated under international law, leading to varied national policies that range from permitting religious use to imposing bans or decriminalization. The United States patent office controversially granted, challenged, revoked, reinstated, and ultimately allowed to expire a patent on the ayahuasca vine, sparking disputes over intellectual property rights and the cultural and religious significance of traditional Indigenous knowledge. Ayahuasca produces intense psychological and spiritual experiences. Ayahuasca's psychoactive effects primarily result from DMT, rendered orally active by harmala alkaloids in B. caapi, which act as reversible inhibitors of monamine oxidase; B. caapi and its β-carbolines also exhibit independent contributions to ayahuasca's effects, acting on serotonin and benzodiazepine receptors. Higher doses of ayahuasca or harmala alkaloids may increase risks.
=== Clinical management === A king cobra's bite, and subsequent envenomation, is an immediate medical emergency in humans or domesticated animals, as, if not treated as soon as possible, death can occur in as little as 30 minutes. Local symptoms include dusky discolouration of skin, edema and pain; in severe cases, swelling extends proximally, with necrosis and tissue sloughing that may require amputation. Onset of general symptoms follows while the venom is targeting the victim's central nervous system, resulting in blurred vision, vertigo, drowsiness, and eventual paralysis. If not treated promptly, it may progress to cardiovascular collapse and, subsequently, coma. Death soon follows due to respiratory failure, among other simultaneous and varied system and organ failures. Polyvalent antivenom of equine origin is produced by Haffkine Institute and King Institute of Preventive Medicine and Research in India. A polyvalent antivenom produced by the Thai Red Cross Society can effectively neutralise venom of the king cobra. Proper and immediate treatments are critical to avoid death. Successful precedents include a client who recovered and was discharged in 10 days after being treated by accurate antivenom and inpatient care. It can deliver up to 420 mg venom in dry weight (400–600 mg overall) per bite, with a LD50 toxicity in mice of 1.28 mg/kg through intravenous injection, 1.5 to 1.7 mg/kg through subcutaneous injection, and 1.644 mg/kg through intraperitoneal injection. For research purposes, up to 1 g of venom was obtained through milking.
This remains a highly contested topic in the academic literature due to disagreements about whether the nocebo effect may play a role, whether self-report questionnaires are reliable for this data, and whether enough objective evidence exists to conclude these effects are persistent after discontinuation of the drug. The Post-Finasteride Syndrome Foundation (PFSF) was created with a medical advisory board to study the topic (finasteride is a similar 5α-reductase inhibitor) and lawsuits alleging harm from the drug are ongoing. Concerns from the PFSF and other patient advocates led the FDA to add a black-box warning to Finasteride for possible risks of suicide in June 2022. Some experts have questioned the basis of the black-box warning, given that it relies on anecdotal patient-reported outcomes rather than prospective trials. Indeed, a 2024 meta analysis of more than 2.2 million patients suggested no causal link between the drug and neurological side effects.
The feud later affected Fat Joe financially as he sought to secure a $20 million contract endorsing Air Jordan sneakers in early 2005, Michael Jordan himself later cancelled the contract following the VMA incident as he was in fear of conflict with 50 Cent or any other affiliates. Following this, little action was taken between G-Unit or Terror Squad as Fat Joe later admitted to pressuring Irv Gotti to end the feud with G-Unit in 2011, though he was unsuccessful. Jadakiss would end his feud with 50 Cent and G-Unit in 2009 in which he performed together with G-Unit at 50 Cent's ThisIs50 Festival on October 3, 2009. Following his release from jail, DMX sought to make amends with Ja Rule via Irv Gotti, in which the two ended their feud at the 2009 VH1 Hip Hop honors. In May 2011, Ja Rule publicly acknowledged his desire to end the feud, claiming "I'm cool. We ain't beefing no more. We'll never collaborate. That's just what it is. You don't have to be at war with somebody, but it's also kind of like U.S. and another country that they may not get along with. We don't gotta go to war, but we're not friends either. But we can coincide inside of a world. He's doing him, and he's not thinking about me, and I'm doing me and I'm not thinking about him." Following the 2012 death of music executive Chris Lighty a tribute concert was thrown in honor. Both 50 Cent and Fat Joe met prior to the performance and ended their feud out of respect for Lighty. The two rappers would later become business associates and friends following the performance.
Sources: en.wikipedia.org
Carbamazepine is relatively slowly but practically completely absorbed after administration by mouth. Highest concentrations in the blood plasma are reached after 4 to 24 hours depending on the dosage form. Slow release tablets result in about 15% lower absorption and 25% lower peak plasma concentrations than ordinary tablets, as well as in less fluctuation of the concentration, but not in significantly lower minimum concentrations. In the circulation, carbamazepine itself comprises 20 to 30% of total residues. The remainder is in the form of metabolites; 70 to 80% of residues is bound to plasma proteins. Concentrations in breast milk are 25 to 60% of those in the blood plasma. Carbamazepine itself is not pharmacologically active. It is activated, mainly by CYP3A4, to carbamazepine-10,11-epoxide, which is solely responsible for the drug's anticonvulsant effects. The epoxide is then inactivated by microsomal epoxide hydrolase (mEH) to carbamazepine-trans-10,11-diol and further to its glucuronides. Other metabolites include various hydroxyl derivatives and carbamazepine-N-glucuronide. The plasma half-life is about 35 to 40 hours when carbamazepine is given as single dose, but it is a strong inducer of liver enzymes, and the plasma half-life shortens to about 12 to 17 hours when it is given repeatedly. The half-life can be further shortened to 9–10 hours by other enzyme inducers such as phenytoin or phenobarbital. About 70% are excreted via the urine, almost exclusively in form of its metabolites, and 30% via the faeces.
biomarker A measurable indicator of some biological state, especially a compound or biomolecule whose presence or absence in a biological system is a reliable sign of a normal or abnormal process, condition, or disease. Things that may serve as biomarkers include direct measurements of the concentration of a particular compound or molecule in a tissue or fluid sample, or any other characteristic physiological, histological, or radiographic signal (e.g. a change in heart rate, or a distinct morphology under a microscope). They are regularly used as predictive or diagnostic tools in clinical medicine and laboratory research.
After World War II, democratic socialist, labourist and social-democratic governments introduced social reforms and wealth redistribution via welfare state social programmes and progressive taxation. Those parties dominated post-war politics in the Nordic countries and countries such as Belgium, Czechoslovakia, France, Italy and the United Kingdom. At one point, France claimed the world's most state-controlled capitalist country, starting a period of unprecedented economic growth known as the Trente Glorieuses, part of the post-war economic boom set in motion by the Keynesian consensus. The public utilities and industries nationalised by the French government included Air France, the Bank of France, Charbonnages de France, Électricité de France, Gaz de France and Régie Nationale des Usines Renault. Outside Europe, the Japan Socialist Party was briefly in power in 1947. In 1945, the British Labour Party led by Clement Attlee was elected to office based on a radical, democratic socialist programme. The Labour government nationalised major public utilities and industries such as mining, gas, coal, electricity, rail, iron, steel and the Bank of England. BP was nationalised in 1951. In 1956, Anthony Crosland stated that at least 25% of British industry was nationalised and that public employees, including those in nationalised industries, constituted a similar proportion of the country's total workforce. The 1964–1970 and 1974–1979 Labour governments strengthened the policy of nationalisation.
Psychiatry is the branch of medicine concerned with the bio-psycho-social study of the etiology, diagnosis, treatment and prevention of cognitive, perceptual, emotional and behavioral disorders. Related fields include psychotherapy and clinical psychology.
=== Traditional methods === Mazatec shamans crush the leaves to extract leaf juices from about 20 to 80 or more fresh leaves (i.e. about 50–200 g or 2–7 oz). They usually mix these juices with water to create an infusion or 'tea' which they drink to induce visions in ritual healing ceremonies. Chewing and swallowing a large number of fresh leaves is the other Mazatec method. Oral consumption of the leaf makes the effects come on more slowly, over a period of 10 to 20 minutes. The experience, from the onset of effects, lasts from about 30 minutes up to one and a half hours. Doses for chewing vastly exceed doses used for smoking. By calculating the concentrations per leaf ("an average concentration of 2.45 mg per gram" of leaf), the average weight per leaf ("about 50 g" per 20 leaves, or 2.5 g/leaf), and the standard dose for chewing (about 8–28 leaves), the doses can range from about 50 mg to 172 mg.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.